After fighting for six years to maintain its patent on Prozac, Eli Lilly and Co. reached the end of the legal road Monday when the U.S. Supreme Court refused to consider the Indianapolis-based drug maker's appeal. Generic versions of Prozac went on the market last year, after a federal appeals court found Lilly improperly double-patented Prozac to extend its exclusive control over the popular antidepressant.
January 14, 2002 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
Honoring outstanding legal achievements focused at the national level, largely around Big Law and in-house departments.
Women Leaders in Consulting Awards honors the industry standouts and rising stars who are making a mark within the profession.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
General Statement of DutiesPerforms legal work involving full litigation of all types of matters both for and against the Town, including al...
Shipman & Goodwin LLP is seeking a attorney to expand our national commercial real estate lending practice. Candidates should have a mi...
Health Law Associate CT Shipman is seeking an associate to join our national longstanding health law practice. Candidates must have t...
